ROSUVASTATIN PROMOTES THE IMPROVEMENT OF NEPHROGENIC MARKERS IN OBSTRUCTIVE NEPHROPATHY MODEL

MAZZEI LUCIANA JORGELINA; GARCÍA ISABEL MERCEDES; DOCHERTY NEIL G; MANUCHA WALTER

San Juan

Congreso; 2° Reunión Conjunta de Sociedades de Biología de la República Argentina, XIII Jornadas de la Sociedad Argentina de Biología, 29° Reunión Científica Anual Sociedad de Biología de Cuyo ,y XVIII Jornadas Científicas de la Sociedad de Biología de Córdoba; 2011

Sociedad Argentina de Biología-Sociedad de Biologia de Cuyo.

Congenital obstructive nephropathy is characterized by tubularapoptosis and fibrosis. Statins prevent apoptotic and fibrotic processesin renal cells. The present study examined whetherrosuvastatin (Ros) could protect against neonatal obstructive nephropathyin the rat in association with the preservation of the expressionof markers of nephrogenesis. Methods: Neonatal rats (n=5)underwent unilateral ureteral obstruction (UUO) or sham surgery(control), were randomized to receive oral Ros (10mg/kg/day) orvehicle for 2 weeks. Renal tissue was processed for quantificationof tubular dilatation, apoptosis, fibrosis, TNF-α, TGF-β1, WT1,Snail, BMP-7 and E-cadherin protein expression. Results: UUOsignificantly increased tubular apoptosis, dilatation and tubuleinterstitialfibrosis coupled to increases in TNF-α and TGF-β1mRNA expression. Ros-treat during UUO markedly protectedagainst these changes. Preservation of renal WT1, Snail, BMP-7and E-cadherin, was also associated to Ros treatment. Conclusions:The protective effects of Ros were sufficient to preserve a normalprofile of expression for a number of markers of nephrogenesissuggesting that renal development is likely to continue despite ofobstruction.